Side-by-side IPO readiness, funding history, and valuation comparison. Data sourced by TechStackIPO.
Scores, valuations, and signals for Absci, Canva, and 370+ companies. 5-min read every Tuesday.
Generative AI drug design company using AI and cell biology to create better biologics faster.
| Industry | Biotechnology |
| Stage | Series C |
| IPO Status | Private |
| Valuation | $2.3B |
| Total Funding | $225M |
| Headquarters | Vancouver, WA |
Canva is the world's leading design platform with 250M+ users — valued at $48B with $770M raised. Track IPO timeline, funding rounds, and readiness score.
| Industry | Design & Creative |
| Stage | Pre-IPO |
| IPO Status | Private |
| Valuation | $42B |
| Total Funding | $770M |
| Headquarters | Sydney, Australia |
Absci is valued at $2.3B. Canva is valued at $42B. Both valuations are based on the most recent private funding rounds tracked by TechStackIPO.
Absci has raised $225M. Canva has raised $770M.
Absci is currently private. Canva is currently private. Track both on TechStackIPO for S-1 filings and IPO announcements.
Absci operates in Biotechnology, while Canva operates in Design & Creative.
Absci is a Biotechnology company valued at $2.3B with $225M raised. Canva is a Design & Creative company valued at $42B with $770M raised. See TechStackIPO's full side-by-side comparison for IPO readiness scores, funding timelines, and investor data.
Accredited investors can access pre-IPO shares in Absci and Canva through secondary market platforms, pre-IPO funds, and broker-dealer platforms that facilitate private company transactions. TechStackIPO's marketplace section tracks available access options for both companies. Pre-IPO investments carry higher risk and limited liquidity.